Anti-Casein Kinase 2 beta (CSNK2B) Rabbit Monoclonal Antibody for WB, IF/ICC, ELISA - P67870

Core Product Specifications and Parameters

Biological Background: Casein Kinase 2 beta (CSNK2B) Function and Localization

• CSNK2B encodes the regulatory beta subunit of Casein kinase II (CK2), a constitutively active serine/threonine kinase that phosphorylates a broad range of substrates containing acidic residues C-terminal to the phosphoacceptor site. Related references: PMID:11239457, PMID:16818610
• The beta subunit assembles with the catalytic alpha subunit to form the tetrameric CK2 holoenzyme, controlling catalytic activity, substrate recognition, and the stability of the complex.
• CK2 beta participates in the Wnt signaling pathway, although its precise mechanistic role requires further elucidation (By similarity).
• During Epstein-Barr virus (EBV) infection, CSNK2B interacts with the viral protein EBNA1, enhancing CK2-mediated phosphorylation and polyubiquitination of PML nuclear bodies, leading to their degradation. Related references: PMID:20719947, PMID:24216761
• CSNK2B further suppresses EBV lytic reactivation by recruiting ARK2N and JUN to the BZLF1 promoter, thereby inhibiting viral transcription. Related references: PMID:31341047
• The protein is predominantly localized to the nucleus, aligning with its functions in transcriptional regulation and chromatin dynamics.
• CSNK2B is subject to diverse post-translational modifications, including acetylation, phosphorylation, and ubiquitination, and features a zinc-binding domain critical for its structural integrity.
• Mutations in CSNK2B are associated with autosomal dominant neurodevelopmental disorders, including epilepsy and intellectual disability, underscoring its importance in central nervous system development and function.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 101–215 of human CSNK2B; sequence alignment suggests high homology across human, mouse, and rat, consistent with the reported cross-reactivity. Verify in your specific sample system.
• For Western blotting, a band at ~25 kDa is expected. Optimize primary antibody concentration (e.g., 1:500–1:2000) and loading controls to confirm specificity.
• In immunofluorescence/ICC, nuclear staining is anticipated; include appropriate fixation and permeabilization protocols, and validate with a nuclear counterstain.
• For ELISA applications, consider using the antibody as a capture or detection reagent after thorough titration and pairing validation.
• Include proper controls such as antigen blocking, knockout cell lines, or siRNA-mediated knockdown to confirm target specificity in functional studies.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. For researchers investigating casein kinase 2 signaling pathways, EBV host interactions, or neurodevelopmental disorders, we ensure consistent supply of validated antibodies like this CSNK2B monoclonal antibody. Beyond single reagents, we offer complementary antibody pairs, bulk ancillary reagents, and custom sourcing solutions for rare or difficult-to-find targets to support your entire development pipeline.